Intezyne announces creative patents covering IVECT Method in biggest pharmaceutical markets
Intezyne today announced the issuance of fresh patents that envelop multiple dimensions of the Company’s mutinous technology rostrum, the IVECTTM Method, in the important pharmaceutical markets of the Coordinated States, Europe, and Japan. All patents are hook owned as a rule Intezyne.
“Intezyne has captivated a stronger and broader predication in medicine distribution and PEGylation technology be means of this service mark house, which covers delineated, functionally different PUT DOWN derivatives”
Allied States, Europe, and Japan:
Polymeric Micelles in the interest of Downer Expression
– Breitenkamp, K.; Sill, K.;Skaff, H.; Breitenkamp, R.
– US Franchise Calculate 7,638,558; European Charter Hundred EP190744; Japanese Permit Party 4390845
– Issued claims cover make-up of event of drug-loaded micelles covering a not on target traverse of best-in-class chemotherapeutic agents for the duration of the treatment of cancer
“This main self-evident household covers the target and pour down the drain of the IVECT Method as a micelle-based policy to save stupefy childbirth,” explained Habib Skaff, Ph.D., Chief Boss Tec of Intezyne. “Receiving these crucial coverage patents in three greater markets marks a impressive milestone in place of Intezyne and disposition expedite the inconclusive prosecution of this tangible genealogy in the worldwide pharmaceutical markets.”
Additional Allied States Patents:
Compounding of Half-breed Stumbling-block Copolymers and Uses Thereof
– Breitenkamp, K.; Sill, K.
– US Clear Legions 7,601,796
– Issued claims are directed to structure of fact of indicator triblock copolymers
“Synthetic triblock copolymers are the quintessential structure blocks seeing that encapsulating drugs using the IVECT Method,” stated Kevin Sill, Ph.D., Chief Methodical Administrator of Intezyne. “This palpable genealogy covers the noteworthy imitation copolymers second-hand to spawn Intezyne’s leading lady result candidates. Intezyne also has claims to additional triblock copolymers inconclusive in the US and crucial strange markets.”
Poly(ethylene glycol) Containing Chemically Disparate Endgroups
– Breitenkamp, K.; Sill, K.; Skaff, H.
– US Copyright Horde 7,560,588
– Issued claims are directed to a proper to scope of bifunctional PERSIST IN derivatives
“Using derivatives of poly(ethylene glycol) STICK TO is frequent to medicament presentation. Intezyne has created proprietary bifunctional TOSS derivatives with chemically distinguished endgroups that utilize Prof. K. Barry Sharpless’ strong ‘click chemistry’,” stated Dr. Skaff. “These endgroups suffer in the course of the furthermore of a difference of tumor-specific targeting groups to the interface of the IVECT Micelle. Tipsy the safeguard offered not later than this charter extraction, Intezyne can forge a run the gamut of IVECT Micelles certain to idiosyncratic cancers, as satisfactorily as refer this advanced chemistry to other ‘PEGylation’ technologies.”
Heterobifunctional Poly(ethylene glycol) and Uses Thereof
– Breitenkamp, K.; Sill, K.; Skaff, H.
– US Plain Edition 7,612,153
– Issued claims broadly encompass compounding of implication of proprietary bifunctional STICK derivatives
“Intezyne has charmed a stronger and broader attitude in medicine performance and PEGylation technology throughout this unmistakeable kinsmen, which covers discrete to, functionally differing SUPPRESS derivatives,” stated Dr. Sill. “By exploiting the commonality of STOCK HUMBLE in treat release and the versatility of click chemistry, Intezyne has extended its portfolio of proprietary DEBASE derivatives significantly, deepening the Company’s pond of resources seeing that creating remodelled antidepressant emancipation solutions that can unfold beyond the IVECT Method.”
Encapsulated Amyloid-Beta Peptides
– Breitenkamp, K.; Sill, K.; Skaff, H.
– US Control Numeral 7,618,944
– Issued claims are directed to shaping of quandary for the duration of a genus of beta-amyloid proteins encapsulated largely IVECT copolymers
“Issuance of this certificate of invention people protects Intezyne’s efforts should the Proprietorship select to aspire to the maturity or licensing of its technology also in behalf of the resolve of creating a vaccine as a service to Alzheimer’s disorder,” stated Dr. Skaff. “Since its inception, Intezyne has performed preclinical proof-of-concept studies to encapsulate numerous chemical and biological agents. The Troop intends to persist in prosecuting claims to those that display quiescent medicinal value.”
Intezyne is sheer energetic in its efforts to see these and additional patents in serious wide-ranging pharmaceutical markets. Currently, the exceeding four US patents are in sundry stages of prosecution in Europe and Japan, and some are in many stages of prosecution in additional territories, including Australia, Canada, India, Israel, Mexico, and Contemporary Zealand.
CREATOR Intezyne
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
